Financials Lonza Group AG Börse Stuttgart

Equities

LO3A

US54338V1017

Biotechnology & Medical Research

Delayed Börse Stuttgart 03:28:56 2024-07-12 am EDT 5-day change 1st Jan Change
52.5 EUR +0.96% Intraday chart for Lonza Group AG +2.97% +41.30%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 26,224 42,255 56,574 33,615 26,273 37,601 - -
Enterprise Value (EV) 1 29,185 45,068 55,616 33,429 27,195 40,335 40,867 40,875
P/E ratio 40.8 x 48.9 x 19.3 x 27.7 x 39.8 x 42.9 x 34.1 x 27.6 x
Yield 0.78% 0.53% 0.39% 0.66% 1.13% 0.87% 1.01% 1.16%
Capitalization / Revenue 4.43 x 6.83 x 10.5 x 5.4 x 3.91 x 5.65 x 4.93 x 4.4 x
EV / Revenue 4.93 x 7.29 x 10.3 x 5.37 x 4.05 x 6.06 x 5.35 x 4.78 x
EV / EBITDA 18 x 26.1 x 33.4 x 16.8 x 13.6 x 22 x 18.7 x 15.9 x
EV / FCF 146 x 287 x -449 x -39.2 x -91.6 x -288 x 837 x 123 x
FCF Yield 0.69% 0.35% -0.22% -2.55% -1.09% -0.35% 0.12% 0.82%
Price to Book 4.03 x 6.2 x 5.82 x 3.18 x 2.76 x 3.86 x 3.65 x 3.37 x
Nbr of stocks (in thousands) 74,246 74,289 74,283 74,189 74,282 72,226 - -
Reference price 2 353.2 568.8 761.6 453.1 353.7 520.6 520.6 520.6
Announcement Date 1/21/20 1/27/21 1/26/22 1/25/23 1/26/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,920 6,185 5,409 6,223 6,717 6,654 7,632 8,552
EBITDA 1 1,624 1,728 1,665 1,995 1,999 1,831 2,183 2,564
EBIT 1 1,249 1,358 1,151 1,397 939 1,167 1,470 1,788
Operating Margin 21.1% 21.96% 21.28% 22.45% 13.98% 17.55% 19.26% 20.9%
Earnings before Tax (EBT) 1 849 986 760 1,448 790 1,057 1,345 1,679
Net income 1 645 869 2,944 1,215 654 872.8 1,097 1,353
Net margin 10.9% 14.05% 54.43% 19.52% 9.74% 13.12% 14.37% 15.82%
EPS 2 8.650 11.63 39.52 16.34 8.880 12.15 15.25 18.83
Free Cash Flow 1 200 157 -124 -852 -297 -140 48.85 333.6
FCF margin 3.38% 2.54% -2.29% -13.69% -4.42% -2.1% 0.64% 3.9%
FCF Conversion (EBITDA) 12.32% 9.09% - - - - 2.24% 13.01%
FCF Conversion (Net income) 31.01% 18.07% - - - - 4.45% 24.65%
Dividend per Share 2 2.750 3.000 3.000 3.000 4.000 4.505 5.250 6.051
Announcement Date 1/21/20 1/27/21 1/26/22 1/25/23 1/26/24 - - -
1CHF in Million2CHF
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 2,944 3,074 3,111 2,542 2,867 2,982 3,241 3,078 3,639 3,012 3,662
EBITDA 1 796 893 835 847 818 987 1,008 922 1,077 801.9 1,046
EBIT 1 606 706 652 606 545 698 699 563 376 478 700.4
Operating Margin 20.58% 22.97% 20.96% 23.84% 19.01% 23.41% 21.57% 18.29% 10.33% 15.87% 19.13%
Earnings before Tax (EBT) 1 407 564 422 296 464 594 854 486 304 411.9 646.4
Net income 1 346 477 392 319 2,625 492 723 410 244 338.1 532.2
Net margin 11.75% 15.52% 12.6% 12.55% 91.56% 16.5% 22.31% 13.32% 6.71% 11.22% 14.53%
EPS 2 4.640 6.390 5.240 4.280 35.24 6.610 9.730 5.540 3.340 4.653 7.270
Dividend per Share 2 - - 3.000 3.000 - - 3.000 3.500 - 4.000 -
Announcement Date 1/21/20 7/24/20 1/27/21 7/23/21 1/26/22 7/22/22 1/25/23 7/21/23 1/26/24 - -
1CHF in Million2CHF
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 2,961 2,813 - - 922 2,734 3,266 3,274
Net Cash position 1 - - 958 186 - - - -
Leverage (Debt/EBITDA) 1.823 x 1.628 x - - 0.4612 x 1.494 x 1.496 x 1.277 x
Free Cash Flow 1 200 157 -124 -852 -297 -140 48.9 334
ROE (net income / shareholders' equity) 10.1% 13.1% 35.5% 11.9% 6.52% 9.03% 10.9% 12.6%
ROA (Net income/ Total Assets) 4.65% 6.15% 19.1% 7.19% 3.82% 5.23% 6.24% 7.35%
Assets 1 13,884 14,135 15,444 16,907 17,103 16,678 17,586 18,402
Book Value Per Share 2 87.60 91.70 131.0 143.0 128.0 135.0 142.0 155.0
Cash Flow per Share 2 13.20 15.10 16.30 13.70 18.80 22.10 24.20 29.40
Capex 1 786 973 1,300 1,872 1,682 1,598 1,606 1,606
Capex / Sales 13.28% 15.73% 24.03% 30.08% 25.04% 24.02% 21.05% 18.78%
Announcement Date 1/21/20 1/27/21 1/26/22 1/25/23 1/26/24 - - -
1CHF in Million2CHF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
520.6 CHF
Average target price
586 CHF
Spread / Average Target
+12.56%
Consensus